Screener
Xenon Pharmaceuticals XENE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's retained earnings?
- Xenon Pharmaceuticals (XENE) reported retained earnings of -$1.46B in Q2 2026.
- How has Xenon Pharmaceuticals's retained earnings changed year-over-year?
- Xenon Pharmaceuticals's retained earnings decreased by 39.0% year-over-year, from -$1.05B to -$1.46B.
- What is the long-term trend for Xenon Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's retained earnings has grown at a 34.9% compound annual growth rate (CAGR), from -$278.49M to -$1.25B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Xenon Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude